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Objective. This study explores the relationship between depressive symptoms, as measured by the PHQ-9 depression screen and
blood glucose levels among patients with diabetes enrolled in Gold Choice, a Medicaid managed care program for individuals
with mental illness and/or substance abuse. Methods. The PHQ-9 was mailed to 454 Gold Choice members and a questionnaire
was mailed to their physicians requesting current HbA1c% and fasting blood glucose (FBG) levels. The pearson product-moment
correlation was used to describe the association between PHQ-9 scores and FBG levels. Results. The PHQ-9 response rate was
55% (N = 249). Laboratory results were received for 141 patients. The correlation between FBG and PHQ-9 scores was modest
but statistically signiﬁcant: r = 0.21 , P = 0.015. Conclusion. A statistically signiﬁcant association was found between FBG and
PHQ-9 depression scores. This ﬁnding supports current recommendationsthatphysiciansbe alert to depressive symptoms among
patients with diabetes or impaired glucose metabolism.
1.Introduction
The co-occurrence of mood disorders and diabetes is
well documented, and both conditions frequently present
together in the primary care setting [1]. Patients with
diabetes and mood disorders exhibit a more severe course
of diabetes, with greater morbidity and higher mortality,
compared to those without mood disorders [2–4]. Broadly
sketched, a similar composite emerges for both conditions,
high prevalence in the general population, low case detec-
tion, protracted illness course high rates of comorbidity,
multifactorial etiology, substantial illness burden and eco-
nomic cost, and association with preventable and premature
excess mortality [5, 6].
Both depression and diabetes are associated with altered
metabolic pathways and stress response networks, resulting
in disruptions in glucose transport and insulin resistance
[7–9]. It remains unknown, however, if the dimensional
severity of depressive symptoms corresponds with the pro-
gressive disruption of glucose homeostasis. Studies that have
explored the relationship between glycemic control and
depressive symptoms have yielded mixed results and the
direction of the association remains unclear [2, 10–16].
In this paper, we explored the relationship between
depressive symptoms, as measured by the 9-item depression
scale of the Patient Health Questionnaire (PHQ-9) and
blood glucose levels among patients with diabetes enrolled
in GoldChoice.GoldChoiceisapartially capitatedMedicaid
managed care program in Western New York for individuals
with serious mental illness and/or substance abuse [17].
T oo u rk n o w l e d g e ,n oe x i s t i n gi n v e s t i g a t i o nh a sp r i m a r i l y
evaluated this relationship in the patient population we have
studied, a subpopulation with a higher risk for disparate
chronic medical disorders.
2.Materialsand Methods
As part of a quality assurance initiative, the PHQ-9 depres-
sion screen was mailed to 454 Gold Choice members diag-
nosed with diabetes, as deﬁned by primary care encounter2 Depression Research and Treatment
Table 1: Characteristics of the sample.
Variable Lab data available N = 141 No lab data N = 108 P value
Demographics
N (%)∗
Gender 0.41
Male 48 (35%) 42 (40%)
Female 91 (66%) 64 (60%)
Age 0.41
18–30 1 (1%) 0 (0%)
31–40 14 (10%) 17 (16%)
41–50 42 (30%) 32 (31%)
50+ 82 (59%) 56 (53%)
Ethnicity 0.06
Hispanic 27 (19%) 28 (27%)
African-American 56 (40%) 51 (49%)
Caucasian 49 (35%) 23 (22%)
Other 7 (5%) 2 (2%)
Depression status
Mean (sd)
PHQ-9 score 10.9 (7.4) 11.1 (6.7) 0.90
N (%)∗
PHQ-9 Score 0.69
≥10 (depressed) 80 (57%) 58 (54%)
<10 (not depressed) 61 (43%) 49 (46%)
PHQ-9 severity level [19] 0.06
Minimal (0–4) 36 (26%) 20 (19%)
Mild (5–9) 25 (18%) 29 (27%)
Moderate (10–14) 26 (18%) 29 (27%)
Moderately severe (15–19) 34 (24%) 15 (14%)
Severe (20–27) 20 (14%) 14 (13%)
Depression diagnosis∗∗ 65 (61%) 42 (39% ) 0.28
∗Some Ns will vary due to missing data.
∗∗Based on primary care encounter data.
data. A total of 249 PHQ-9 screens were completed and
returnedtoGoldChoice.Characteristicsofthisinitialsample
have been described elsewhere [17].
Physician Self-Assessment (PSA) surveys were sent to the
primary care providers of the 249 patients that completed
the PHQ-9 requesting the last-known HbA1c% and fasting
bloodglucoselevels(laboratory data).ThePSAisabriefself-
report questionnaire that Gold Choice uses as an alternative
to full-scale chart audits as well as to assess guideline
adherence for standards of care as outlined in the Gold
Choice Quality Assurance Plan [18].
Data analyses were conducted using SPSS 16.0 (Chicago,
Ill, USA). Chi-square tests, t-tests, analysis of variance
(ANOVA), and Pearson’s correlation were used as appro-
priate. A one-sample Kolmogorov-Smirnov test conﬁrmed
normality of the distribution of PHQ-9 scores. All tests were
two sided, and a P value < 0.05 was considered statistically
signiﬁcant. This project was approved by the University of
Toronto Institutional Review Board.
3.Results
In the initial study, there were no statistically signiﬁcant
diﬀerences observed between the 249 Gold Choice members
completing the PHQ-9 and the 205 who did not return
a completed screen with respect to gender or age [17]. A
total of 163/249 (65%) PSA surveys were received from the
primary care providers. Fasting blood glucose (FBG) and/or
HbA1c laboratory results were available on 141 patients of
the 163 PSA surveys that were returned to Gold Choice.
Demographic data and depression status were compared
for the patients for whom laboratory results were available
and those for whom results were not available. Table 1 shows
the demographic characteristics and depression status of the
sample. No statistically signiﬁcant diﬀerences were observed
between the two groups with respect to gender, age, or
ethnicity.
There were no statistically signiﬁcant diﬀerences in
depression status, as measured by the PHQ-9 score, andDepression Research and Treatment 3
depression diagnosis between the group for whom labo-
ratory results were received compared to those for whom
laboratory results were not available.
Because the chi-square results for ethnicity and PHQ-
9 severity level between the two groups approached signiﬁ-
cance(P = 0.06),weundertookadditionalchi-squareteststo
explore a possible association between ethnicity and depres-
sion severity, as measured by PHQ-9 score. We observed
a statistically signiﬁcant association between ethnicity and
depression severity (P = 0.011), with Hispanic patients
scoring higher than the other three groups in the moderately
severe depression and severe Depression categories (data not
shown). Furthermore, mean FBG concentrations did not
signiﬁcantly vary by ethnic group (P = 0.697)
Over half of the participants (55%) in the total sample
of 249 screened positive for moderate depression (PHQ-9 ≥
10).The meanHbA1c% was7.27 (±1.7),and the mean FBG
was 138mg/dL (±68). While the correlation between HbA1c
and PHQ-9 scores was not statistically signiﬁcant, there was
a signiﬁcant association between FBG and the PHQ-9 scores:
r = 0.21, P = 0.015. There was a moderately strong
correlation between HbA1c and FBG: r = 0.53, P<0.001.
4.Conclusions
We observed a positive correlation between elevated fasting
blood glucose and elevated PHQ-9 depression scores among
patients diagnosed with diabetes. Moreover, we found few
diﬀerences between patients for whom laboratory values
were available and those for whom laboratory values were
not available. We had anticipated that the latter group might
have had worse depression, reﬂected in a lower receipt of
laboratory tests. Our results suggest that Hispanic patients in
the sample may have had more severe depressive symptoms
than the other groups. The focus of a separate analysis
may attempt to parse factors that portend a greater risk in
Hispanic individuals.
The present study extends and expands the growing
literature documenting the relationship between glucose
metabolism and depressive symptoms [10, 11, 14, 16,
20]. The cross-sectional design of this study cannot show
cause/eﬀect between elevated fasting blood glucose and
depressive symptoms. It may be notable, however, that sev-
eral previous studies have suggested that depressed patients
experience improved glucose metabolism after treatment
with antidepressants as well as cognitive behavioral therapy
[21–23].
To our knowledge, this is the ﬁrst study to evaluate the
relationship between fasting blood glucose and depressive
symptoms in a Medicaid managed care population of
individuals with serious mental illness and/or substance
abuse. Study limitations include a relatively small sample.
Depression assessment was based on self-report (PHQ-9)
rather than a diagnostic psychiatric interview (e.g., SCID).
Because Gold Choice is a partially capitated managed-care
organization that is reimbursed by Medicaid for patients’
primary care services only, it does not have access to
specialty or behavioral healthcare data, including psychiatric
diagnoses, unless the member shares this information with
his/her primary care physician, which is then transmitted
to Gold Choice via primary care encounter data. These
limitations reﬂect the methodological challenges inherent in
collecting and assessing complex patient data in a Medicaid
population, as well as eliciting patient information from
physicians.
These ﬁndings need to be replicated in a larger sample
in the general population of individuals without an existing
diabetes diagnosis. Nonetheless, our preliminary ﬁnding
lends further credence to current recommendations that
physicians be alert to the presence of depressive symp-
toms among patients with diabetes or impaired glucose
metabolism.
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